The advent of new imaging modalities has greatly aided the understanding of neovascular age-related macular degeneration (AMD). Dr Roberto Gallego-Pinazo claims that much of this progress can be attributed to structural optical coherence tomography (OCT). In this interview, filmed at AAO 2018, Dr Gallego-Pinazo discusses the importance of structural OCT and other types of imaging in the diagnosis and treatment of neovascular AMD. He also describes how fluorescein angiography has made it possible to divide neovascularisations into classic and occult, and how structural OCT has advanced this further, allowing the differentiation of neovascular subtypes 1, 2 and 3. Finally, Dr Gallego-Pinazo discusses how better education is required in terms of analysing the information provided by structural OCT in order to determine accurate treatment endpoints, and how self-monitoring devices and telemedicine are the next step forward in neovascular AMD.
1. What are the most useful imaging modalities in the diagnosis and monitoring of neovascular age-related macular degeneration (AMD)? (0:11)
2. How has multimodal imaging impacted on our understanding of neovascular AMD? (0:44)
3. How has these new insights affected the classification of neovascular AMD and what are the clinical implications of this? (1:45)
4. What biomarkers of neovascular activity have proven useful in multimodal imaging? (2:48)
5. What are the remaining unmet needs in this area? (3:45)
Speaker disclosures: Roberto Gallego-Pinazo has nothing to disclose in relation to this interview.
Filmed at the American Academy of Ophthalmology (AAO) 2018 Annual Meeting, Chicago, IL, US, 27–30 October 2018.
Share this Video
Related Videos In Retina/Vitreous
David Boyer, ARVO 2023: Phase IIb RESTORE trial: MCO-010 optogenetic therapy for vision restoration in patients with retinitis pigmentosa
The RESTORE trial (NCT04945772) is a phase 2b randomized, sham-controlled, multi-centre, multi-dose, double-masked clinical trial evaluating the efficacy and safety of MCO-010 optogenetic therapy in adults with retinitis pigmentosa. MCO-010 is an ambient-light activatable Multi-Characteristic Opsin (MCO) optogenetic therapy for vision restoration. It was a pleasure to speak with Prof. David Boyer (Retina Vitreous Associates Medical […]
David Boyer, ARVO 2023: Retinitis Pigmentosa and the unmet needs in its treatment
Retinitis pigmentosa is an inherited retinal dystrophy (IRD) caused by the loss of photoreceptors and characterized by retinal pigment deposits visible on fundus examination. Retinitis pigmentosa is the most common group of IRD. It was a pleasure to speak with Prof. David Boyer (Retina Vitreous Associates Medical Group, Los Angeles, CA, USA) around Retinitis Pigmentosa […]
Carl Regillo, Hawaiian Eye and Retina 2023: New and emerging treatments for neovascular age-related macular degeneration
It was a pleasure to catch up with Dr Carl Regillo (Wills Eye Hospital, Philadelphia, PA, USA) about new and emerging neovascular age-related macular degeneration treatments, including the new anti-vascular endothelial growth factor which appear to lead to better outcomes with durability, which is one of the biggest unmet needs in treatment of age-related macular […]